Impact of neoadjuvant chemotherapy on long-term prognosis for borderline resectable pancreatic cancer treated with combined allogeneic vascular replacement
10.3760/cma.j.cn113884-20220307-00094
- VernacularTitle:新辅助化疗对术中联合同种异体血管置换的交界可切除胰腺癌预后的影响
- Author:
Jincan HUANG
1
;
Fei PAN
;
Tao JIANG
;
Jing WANG
;
Qing CHEN
;
Mengxiu HUANG
;
Qiang HE
;
Ren LANG
Author Information
1. 首都医科大学附属北京朝阳医院肝胆外科，北京 100020
- Keywords:
Pancreatic neoplasms;
Neoadjuvant chemotherapy;
Prognosis;
Allogeneic vascular replacement
- From:
Chinese Journal of Hepatobiliary Surgery
2022;28(8):582-586
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the impact of neoadjuvant chemotherapy on long-term prognosis of patients with borderline resectable pancreatic cancer (BRPC) treated with combined allograft revascularization.Methods:The data of patients with BRCP who were treated at Beijing Chaoyang Hospital, Capital Medical University from March 2016 to March 2021 were retrospectively analysed. Of 52 patients who underwent radical surgery combined with allograft revascularization in this study, there were 24 males and 28 females, aged (60.3±10.6) years old. These patients were divided into two groups based on whether they received neoadjuvant chemotherapy before surgery. There were 19 patients in the neoadjuvant chemotherapy group and 33 patients in the vascular replacement group. Outpatient clinic and telephone follow-up were used. The clinical data and prognostic differences between the two groups were then analysed.Results:Of 52 patients who underwent surgery successfully, 14 patients (26.9%) developed postoperative complications. The incidence of postoperative pancreatic fistula was significantly lower in the neoadjuvant chemotherapy group than the vascular replacement group (0 vs. 21.2%, P<0.05). The median survivals were 15 and 13 months in the neoadjuvant chemotherapy and the vascular replacement groups, respectively, with a significant difference in cumulative postoperative survival between the two groups ( P=0.039). For patients with BRPC, CA19-9>400 U/ml ( RR=4.540, 95% CI: 2.332-8.836, P<0.001) was an independent risk factor for long-term survival after surgery. Conclusions:Neoadjuvant chemotherapy reduced the incidence of postoperative pancreatic fistula and improved survival prognosis in patients with BRPC. A high preoperative serum CA19-9 level was an independent risk factor for long-term survival in patients with BRPC.
